预约演示

更新于：2025-09-23

Durvalumab

度伐利尤单抗

更新于：2025-09-23

概要

基本信息

药物类型

单克隆抗体

别名

Durvalumab (Genetical Recombination)、Durvalumab (genetical recombination) (JAN)、Durvalumab (USAN/INN)

+ [10]

靶点

PDL1

作用方式

抑制剂

作用机制

PDL1抑制剂(程序性死亡配体1抑制剂)

治疗领域

肿瘤消化系统疾病呼吸系统疾病+ [11]

在研适应症

肌层浸润性膀胱癌子宫癌晚期子宫内膜癌+ [193]

非在研适应症

急性髓性白血病肺腺癌前列腺腺癌+ [76]

原研机构

在研机构

+ [17]

非在研机构

Fred Hutchinson Cancer Research Center

Plexxikon, Inc.

Mirati Therapeutics, Inc.

+ [6]

权益机构

MedImmune Pharma BV

Ultimovacs ASAVall d'Hebron Institut d'Oncologia

+ [14]

最高研发阶段批准上市

首次获批日期

美国 (2017-05-01),

尿路上皮癌

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、突破性疗法 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (澳大利亚)、优先审评 (澳大利亚)、孤儿药 (日本)

登录后查看时间轴

结构/序列

Sequence Code 10069506H

来源: *****

Sequence Code 13384675L

来源: *****

关联

883

项与度伐利尤单抗相关的临床试验

NCT07122089

/ Not yet recruiting临床2期IIT

A Multicenter Open-label, Prospective Study to Evaluate the Efficacy and Safety of SIRT Using Yttrium-90 Glass Microspheres Followed by Durvalumab and Tremelimumab for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, being the third leading cause of cancer-related death worldwide, with approximately 745 000 deaths reported annually.
For advanced patients, including patients with tumoral portal vein thrombosis (PVT), most treatment guidelines recommend systemic therapy, either combination immunotherapy (IO) or combination of immunotherapy and anti-angiogenic treatment for first line option.
Results for PVT patients are provided in one trial with a median overall survival of 14.2 months with IO underlying the necessity to improve treatment of PVT patients. Two recent other phase 3 trials also reported positive results for different IO regimen.
Selective internal radiation therapy (SIRT) using yttrium-90 (90Y)-loaded glass microspheres (TheraSphereTM) can be used for patients with early stage to locally advanced HCC including PVT patients without extrahepatic spread (EHS). TheraSphereTM is recognized and is reimbursed in France for PVT patients without EHS, since 2019.Several retrospective studies have shown promising results for PVT patients.
Nowadays use of SIRT in locally advanced HCC is regaining interest based on the results of the randomized DOSISPHERE-01 study including non-operable patients, about 70% with PVT. This randomized Phase II trial using 90Y-loaded microspheres sought was noted the effectiveness of 90Y-loaded microspheres using a personalized dosimetry approach versus a standard dosimetry approach.
The use of a systemic treatment as IO after a locoregional treatment with the strong local debulking effect of SIRT is logical and of interest. Indeed, the most frequent pattern of progression after SIRT is recurrence in an untreated area, including untreated liver or EHS. Patients are then usually referred to IO.
Such kind of therapeutic approach, using SIRT followed by IO has already been evaluated in a phase 2 study using nivolumab after 90Y loaded resin microspheres with promising efficacy without safety deterioration.
The aim of this study is to evaluate SIRT followed by IO used according to their current indications in advanced HCC patient with PVT patients and without EHS.

开始日期2026-01-02

申办/合作机构

Center Eugene Marquis

[+1]

NCT05403723

/ Suspended临床1期IIT

A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination With Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer

This is trial studying the safety of adaptive stereotactic body radiotherapy (SBRT) combined with durvalumab immunotherapy, platinum chemotherapy, and etoposide chemotherapy in platinum refractory extensive stage small cell lung cancer (SCLC).

开始日期2025-12-31

申办/合作机构

University of Maryland Baltimore

[+1]

NCT07172412

/ Not yet recruiting临床2期IIT

An Umbrella Ib/II Phase Study Evaluating the Efficacy and Safety of First-Line Combination Therapy in the Treatment of Extensive-Stage Small Cell Lung Cancer

This is an open-label umbrella study conducted in first treatment ES-SCLC patients, employing a novel umbrella trial design (biomarker-integrated multi-arm trial with a shared ICI+chemotherapy control arm). Eligible patients were assigned to trial arms based on biomarker expression levels. Biomarker subgroups were defined as: (1) High ASCL1/NEUROD1/DLL3 expression: DLL3-CAR-NK cells combined with ICI + etoposide + carboplatin (DLL3 group); (2) Myc overexpression: XPO1 inhibitor selinexor combined with ICI + etoposide + carboplatin (XPO1 group); (3) VIM/AXL high expression group treated with anlotinib combined with ICI + etoposide + carboplatin (anlotinib group).

开始日期2025-11-01

申办/合作机构

天津市肿瘤医院（天津医科大学肿瘤医院）

100 项与度伐利尤单抗相关的临床结果

登录后查看更多信息

100 项与度伐利尤单抗相关的转化医学

登录后查看更多信息

100 项与度伐利尤单抗相关的专利（医药）

登录后查看更多信息

2,288

项与度伐利尤单抗相关的文献（医药）

2025-12-31·OncoImmunology

Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab

Article

作者: Srivastava, Raghvendra M ; Makarov, Vladimir ; Rupani, Amit ; Chan, Timothy A ; Osborne, Nicole

Several FDA-approved anti-PD-L1 (programmed cell death ligand-1) monoclonal antibodies (mAbs) are used to treat cancer. While these mAbs primarily target and intercept PD-L1:PD-1 inhibitory signaling in T-cells, the Fc-domains of these mAbs are distinct, and the unique cellular cascades triggered by differing Fc-domains of PD-L1 mAbs have not been directly investigated. In this study, we compared the innate immune effects of two widely used anti-PD-L1 IgG1 mAbs which bear distinct Fc-domains, avelumab (native-Fc) and durvalumab (mutated-Fc), using two-cell and three-cell co-culture systems containing Natural Killer cells (NK-cells), dendritic cells (DCs) and various tumor cell lines of multiple cancer origins. We show a robust enhancement in NK-cell effector function, DC maturation, reciprocal NK:DC crosstalk and DC editing that is unique to avelumab treatment using multiple functional immune assays. By transcriptomic analysis, we show for the first time pivotal differences in gene sets involved in NK-cell effector function, DC maturation, immunoregulatory interactions, and cytokine production between innate immune cells treated with avelumab versus durvalumab. Furthermore, we report several previously unknown Fc-receptor-associated biological pathways uniquely triggered by avelumab. Our findings elucidate novel mechanisms of Fc-dependent actions of PD-L1 mAbs which may inform their use in future clinical trials.

2025-12-31·Human Vaccines & Immunotherapeutics

From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment

Review

作者: Fang, Ye-Ying ; Chen, Gang ; Huang, Fang-Ju ; He, Rong-Quan ; Su, Qin-Yan ; Wen, Jia-Ying ; Li, Jian-Jun ; Qin, Di-Yuan ; Chi, Bang-Teng ; Chen, Yi-Yang ; Zeng, Jian-Jia ; Wang, Lei ; Yang, Li-Hua ; Lin, Qian

Cholangiocarcinoma (CCA) is a highly malignant hepatobiliary tumor characterized by limited treatment options and poor prognosis. The recent rise of immunotherapy has significantly influenced research in this field. This study presents a bibliometric analysis of 416 articles retrieved from the WOSCC, Wan fang Data, CNKI and VIP databases, spanning contributions from 32 countries, 589 institutions and 3,200 authors. The analysis identified "PD-L1," "PD-1" and "pembrolizumab" as central research foci, while "immune checkpoint inhibitors," "tumor immune microenvironment," "tertiary lymphoid structures" and "durvalumab" emerged as key areas of interest. These findings emphasize the pivotal role of immunotherapy in improving survival outcomes for CCA, and they highlight the significance of tertiary lymphoid structures within the tumor microenvironment as a promising target for future research. This study offers a strategic overview of the evolving landscape of CCA immunotherapy, providing valuable insights to guide future scientific endeavors in this domain.

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of perioperative nivolumab + neoadjuvant platinum doublet chemotherapy as treatment for resectable non-small cell lung cancer in the United States

Article

作者: Milev, Sandra ; White, Benjamin ; Harris, Mack ; Sun, Ariel ; Lucherini, Stefano ; Villacorta, Reginald

AIMS:

CheckMate-77T demonstrated the clinical benefit of perioperative nivolumab plus neoadjuvant platinum-doublet chemotherapy (periNivo + neoCT). This study assessed the cost-effectiveness of periNivo + neoCT as treatment for non-metastatic (Stage IIA-IIIB), resectable non-small cell lung cancer (NSCLC) vs. relevant comparators in the US.

MATERIALS AND METHODS:

Following the natural history of non-metastatic NSCLC, a four-state Markov model was developed. Modeled health states were event-free survival, locoregional recurrence, distant metastasis, and death. CheckMate-77T informed time to progression estimates for periNivo + neoCT and neoCT; mortality estimates leveraged longer-term follow-up available from CheckMate-816. Indirect treatment comparison informed efficacy of comparator treatments not considered in CheckMate-77T. Comparators were neoadjuvant treatment strategies (neoadjuvant nivolumab + chemotherapy [neoNivo + CT], neoadjuvant chemotherapy [neoCT], and neoadjuvant chemoradiotherapy [neoCRT]), adjuvant chemotherapy (adjCT), and perioperative immuno-therapy (IO) strategies (perioperative durvalumab + neoadjuvant chemotherapy [periDurva + neoCT] and perioperative pembrolizumab + neoadjuvant chemotherapy [periPembro + neoCT]). Cost inputs were obtained from published literature and standard US sources and expressed in 2024 USD. The base-case analysis adopted the perspective of a commercial payer with a lifetime time horizon and discounted cost and health outcomes by 3% annually.

RESULTS:

Model results showed that periNivo + neoCT is more effective and costly than comparators. Deterministic incremental cost-effectiveness ratios were $84,921, $153,557, $77,976, $60,826, $74,252, $32,069, and $21,974 vs. neoCT, neoNivo + CT, neoCRT, adjCT, surgery, periPembro + neoCT, and periDurva + neoCT, respectively. In probabilistic sensitivity analysis, periNivo + neoCT resulted in an ICER below $150,000/QALY in 93.3%, 58.2%, 82.4%, 95.1%, 98.3%, 69.9%, and 82.1% of iterations vs. neoCT, neoNivo + CT, neoCRT, adjCT, surgery only, periPembro + neoCT, and periDurva + neoCT, respectively.

LIMITATIONS:

Uncertainty in the survival extrapolations reflected the limited body of evidence informing the indirect treatment comparison. ICERs vs. perioperative IO treatment strategies were sensitive to small changes in predicted costs and QALYs, given low incremental base case costs and QALYs.

CONCLUSION:

PeriNivo + neoCT is a cost-effective treatment option for patients with resectable, non-metastatic NSCLC.

1,822

项与度伐利尤单抗相关的新闻（医药）

2025-09-23

·ioncology

ESMO 2025丨LBA重磅发布，胸部肿瘤领域抢先看！

点上方蓝字“ioncology”关注我们，然后点右上角“…”菜单，选择“设为星标” 2025年欧洲肿瘤内科学会年会（ESMO 2025）将于10月17~21日在德国柏林盛大举行。作为全球肿瘤学领域最具影响力的学术盛会之一，本届大会将集中呈现肿瘤诊疗领域的突破性研究进展。今日，大会官网公布LBA（Late-breaking Abstract）摘要入选研究标题，其中胸部肿瘤领域18项研究成果入选，3项研究成果来自中国。《肿瘤瞭望》特将胸部肿瘤领域LBA入选研究标题进行整理，以飨读者。转移性非小细胞肺癌摘要号：LBA72 摘要标题：NorthStar: A Phase II Randomized Study of Osimertinib (OSI) With or Without Local Consolidative Therapy (LCT) for Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) 中文标题：NorthStar：奥希替尼（OSI）联合或不联合局部巩固治疗（LCT）用于转移性 EGFR 突变型非小细胞肺癌（NSCLC）的 II 期随机研究讲者：Yasir Y. Elamin（美国）摘要号：LBA75 摘要标题：Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study 中文标题：Sevabertinib（BAY 2927088）治疗晚期HER2突变型非小细胞肺癌（NSCLC）：SOHO-01研究结果讲者：乐秀宁教授（美国）摘要号：LBA74 摘要标题：Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1 中文标题：Zongertinib作为晚期HER2突变型非小细胞肺癌（NSCLC）患者的一线治疗：Beamion LUNG 1研究讲者：Sanjay Popat（英国）摘要号：LBA77 摘要标题：FLAURA2: exploratory overall survival (OS) analysis in patients (pts) with poorer prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment (tx) for EGFR-mutated (EGFRm) advanced NSCLC 中文标题：FLAURA2：奥希替尼（osi）联合或不联合铂类-培美曲塞化疗（CTx）一线（1L）治疗EGFR突变型（EGFRm）晚期非小细胞肺癌（NSCLC）中，具有较差预后因素患者的探索性总生存期（OS）分析讲者：Pasi A. Jänne（美国）摘要号：LBA73 摘要标题：Final overall survival (OS) and safety analysis of the Phase 3 ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC) 中文标题：ALEX III期研究的最终总生存期（OS）和安全性分析：阿来替尼（alectinib）对比克唑替尼（crizotinib）治疗既往未接受过治疗的晚期ALK阳性（ALK+）非小细胞肺癌（NSCLC）患者讲者：Tony S.K. Mok（中国香港中文大学）摘要号：LBA71 摘要标题：Final Analysis of First-Line Serplulimab Plus Chemotherapy With or Without HLX04 in Advanced Nonsquamous Non-small Cell Lung Cancer: the ASTRUM-002 Phase 3 Study 中文标题：一线斯鲁利单抗（Serplulimab）联合化疗±HLX04治疗晚期非鳞非小细胞肺癌的最终分析：III期ASTRUM-002研究讲者：石远凯教授（中国医学科学院肿瘤医院）摘要号：LBA76 摘要标题：Paclitaxel-bevacizumab ± atezolizumab in advanced non-squamous NSCLC progressing after chemo-immunotherapy: IFCT-2201 ADAPTABLE randomized phase II trial 中文标题：紫杉醇-贝伐珠单抗±阿替利珠单抗（atezolizumab）治疗chemo-免疫治疗后进展的晚期非鳞非小细胞肺癌（NSCLC）：II期随机IFCT-2201 ADAPTABLE试验讲者：Arnaud Scherpereel（法国）非转移性非小细胞肺癌及小细胞肺癌摘要号：LBA65 摘要标题：Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: interim analysis (IA) of the phase 2 MDT-BRIDGE study 中文标题：可切除或临界可切除IIB–IIIB期非小细胞肺癌（NSCLC）患者的新辅助度伐利尤单抗（D）+化疗（CT），后续接受手术（Sx）联合辅助度伐利尤单抗或放化疗（CRT）联合巩固度伐利尤单抗治疗：II期MDT-BRIDGE试验的中期分析（IA）讲者：Yasir Y. Elamin（美国）摘要号：LBA69 摘要标题：SKYSCRAPER-03: Phase 3, open-label, randomised study of atezolizumab (atezo) + tiragolumab (tira) vs durvalumab (durva) in locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) after platinum-based concurrent chemoradiation (cCRT) 中文标题：SKYSCRAPER-03：III期、开放标签、随机研究：阿替利珠单抗（atezo）+tiragolumab对比度伐利尤单抗（durva）治疗铂类同步放化疗（cCRT）后局部晚期、不可切除的 III 期非小细胞肺癌（NSCLC）讲者：Rafal Dziadziuszko（波兰）摘要号：LBA100 摘要标题：Detailed safety analysis of DeLLphi-304: the first phase 3 study to evaluate tarlatamab versus chemotherapy for previously treated small cell lung cancer 中文标题：DeLLphi-304 试验的详细安全性分析：首个评估tarlatamab对比化疗治疗既往接受过治疗的小细胞肺癌（SCLC）的 III 期研究讲者：Martin H. Schuler（德国）摘要号：LBA101 摘要标题：Tarlatamab as second-line (2L) treatment for small cell lung cancer (SCLC): Outcomes by chemotherapy-free interval (CFI) and prior PD-(L)1 inhibitor use in the phase 3 DeLLphi-304 trial 中文标题：Tarlatamab作为小细胞肺癌（SCLC）二线（2L）治疗：III 期 DeLLphi-304 试验中按无化疗间隔（CFI）和既往 PD-(L) 1 抑制剂使用情况分层的疗效结局讲者：Pedro F. Simoes da Rocha（西班牙）摘要号：LBA66 摘要标题：Ensartinib as adjuvant therapy in patients (pts) with stage IB–IIIB ALK-positive (ALK+) non-small cell lung cancer (NSCLC) after complete tumor resection: the phase III randomized ELEVATE trial 中文标题：恩沙替尼（Ensartinib）作为IB–IIIB期ALK阳性（ALK+）非小细胞肺癌（NSCLC）肿瘤完全切除术后的辅助治疗：III期随机ELEVATE试验讲者：岳东升教授（天津医科大学肿瘤医院）摘要号：LBA67 摘要标题：Perioperative Pembrolizumab in Early-Stage Non–Small-Cell Lung Cancer (NSCLC): 5-Year Follow-Up From KEYNOTE-671 中文标题：早期非小细胞肺癌（NSCLC）围手术期帕博利珠单抗（Pembrolizumab）治疗：KEYNOTE-671试验的5年随访结果讲者：Heather Wakelee （美国）摘要号：LBA68 摘要标题：CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): final overall survival (OS) and minimal residual disease (MRD) analyses. 中文标题：CCTG BR.31：度伐利尤单抗（D）辅助治疗已切除非小细胞肺癌（NSCLC）：最终总生存期（OS）和微小残留病（MRD）分析讲者：Glenwood Goss（加拿大）摘要号：LBA70 摘要标题：Association of radiomic features ± on-treatment ctDNA detection with treatment outcomes in patients with resectable NSCLC: exploratory analyses from AEGEAN 中文标题：影像组学特征 ± 治疗中循环肿瘤 DNA（ctDNA）检测与可切除非小细胞肺癌（NSCLC）患者治疗结局的相关性：AEGEAN 试验的探索性分析讲者：John Heymach（美国）胸腺间皮瘤摘要号：LBA104 摘要标题：Primary results of DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial 中文标题：DREAM3R试验的主要结果：度伐利尤单抗（Durvalumab）联合化疗作为晚期胸膜间皮瘤的一线治疗 —— 一项 III 期随机试验讲者：Anna K. Nowak（澳大利亚）摘要号：LBA105 摘要标题：A Phase II, Open-label, Single-arm, Multi-center Study of Rivoceranib in Patients with Metastatic Thymic Epithelial Tumor, KCSG LU23-09 (THRIVE) 中文标题：Rivoceranib治疗转移性胸腺上皮肿瘤患者的II期、开放标签、单臂、多中心研究：KCSG LU23-09 试验（THRIVE）讲者：Myung-Ju Ahn（韩国）摘要号：LBA106 摘要标题：3D-response and multiomic correlates of Niraparib in relapsed mesothelioma: NERO, a randomised clinical trial in patients with relapsed mesothelioma 中文标题：尼拉帕利（Niraparib）治疗复发性间皮瘤的三维疗效（3D-response）及多组学相关性：NERO 试验（一项复发性间皮瘤患者的随机临床试验）讲者：Dean A. Fennell（英国）排名不分先后，按照摘要类别划分；如有遗漏或任何问题，请后台留言（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果临床2期临床3期

2025-09-23

·ioncology

ESMO 2025丨LBA重磅发布，妇科肿瘤领域研究盘点！

点上方蓝字“ioncology”关注我们，然后点右上角“…”菜单，选择“设为星标” 2025年欧洲肿瘤内科学会（ESMO）年会将于10月17~21日在德国柏林举行。大会官网公布了LBA（Late-breaking Abstract）摘要入选研究标题，《肿瘤瞭望》特将妇科肿瘤领域LBA研究以及之前已公布的口头报告内容进行整理，以飨读者。优选口头报告（Proffered paper session）摘要号：LBA38 摘要标题：卡瑞利珠单抗联合法米替尼对比铂类化疗作为复发或转移性宫颈癌一线治疗的III期研究 Phase 3 study of camrelizumab plus famitinib versus platinum-based chemotherapy as first-line therapy for recurrent or metastatic cervical cancer 讲者：吴小华（复旦大学附属肿瘤医院）摘要号：LBA39 摘要标题：评估阿替利珠单抗联合紫杉醇和卡铂治疗晚期/复发性子宫内膜癌的随机双盲III期AtTEnd/ENGOT-EN7试验的最终总生存期结果 Final overall survival (OS) results from the randomized double-blind phase III AtTEnd/ENGOT-EN7 trial evaluating atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer 讲者：Maria Pilar Barretina Ginesta (西班牙赫罗纳 ) 摘要号：1063O 摘要标题：氟唑帕利单药或联合阿帕替尼一线维持治疗晚期卵巢癌：FZOCUS-1研究最终分析 Fuzuloparib （FZPL） monotherapy or in combination with apatinib （APA） as first-line （1L） maintenance therapy in advanced ovarian cancer （OC）: final analysis of the FZOCUS-1 trial 讲者：李宁（中国医学科学院肿瘤医院）摘要号：1064O 摘要标题：ICON8B：GCIG III期随机试验，比较一线每周剂量密集化疗+贝伐珠单抗vs.三周化疗+贝伐珠单抗治疗高危III-IV期上皮性卵巢癌患者的疗效：最终总生存（OS）分析 ICON8B: GCIG Phase III Randomised Trial Comparing First-line Weekly Dose-Dense Chemotherapy + Bevacizumab To Three-Weekly Chemotherapy + Bevacizumab In High-Risk Stage III-IV Epithelial Ovarian Cancer （EOC）: Final Overall Survival （OS） Analysis 讲者：Andrew R. Clamp（英国曼彻斯特）摘要号：LBA42 摘要标题：Raludotatug deruxtecan（R-DXd）治疗铂耐药卵巢癌（PROC）患者：REJOICE-Ovarian01研究II期剂量优化部分的主要分析 Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): primary analysis of the Phase 2 dose-optimization part of REJOICE-Ovarian01 讲者：Isabelle L. Ray-Coquard (法国里昂) 微型口头报告（Mini Oral session）摘要号：LBA40 摘要标题：WES来源的非整倍体评分（W-AS）可识别出从免疫治疗中获益减少的子宫内膜癌MMRd患者：对III期AtTEnd/ENGOT-EN7试验的多组学分析 WES-derived Aneuploidy score (W-AS) identifies MMRd patients with reduced benefit from immunotherapy in endometrial cancer. Multi-omic analysis of the phase III AtTEnd/ENGOT-EN7 trial 讲者：Luca Mazzarella (意大利米兰) 摘要号：LBA41 摘要标题：基线多重细胞因子谱分析在复发卵巢癌（rOC）III期ANITA试验中鉴定出预后特征 Baseline (BL) multiplex cytokine profiling identifies prognostic signatures in the phase 3 ANITA (ENGOT-Ov41/GEICO 69-O) trial in recurrent ovarian cancer (rOC) 讲者：Antonio González-Martín（西班牙马德里）摘要号：1065MO 摘要标题：一种针对叶酸受体α（FRα）的ADC药物AZD5335在铂耐药复发性卵巢癌患者中的首次人体研究 First-in-human study of AZD5335, a folate receptor α （FRα）-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer 讲者：Ana Oaknin（西班牙巴塞罗那）摘要号：LBA43 摘要标题：NAPISTAR 1-01：TUB-040（一种新型靶向NaPi2b的依沙替康ADC）在铂耐药卵巢高级别浆液性癌患者中的1期剂量递增研究 NAPISTAR 1-01: A Phase 1 dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate (ADC) in patients with platinum-resistant ovarian (PROC) high grade serous carcinoma (HGSC) 讲者：Antonio González-Martín (西班牙马德里) 摘要号：LBA44 摘要标题：DUO-O试验（ENGOT-ov46/GOG-3025）最终总生存数据：对于新诊断非BRCA突变晚期卵巢癌患者，度伐利尤单抗+紫杉醇/卡铂+贝伐珠单抗诱导治疗后，使用度伐利尤单抗、贝伐珠单抗和奥拉帕利维持治疗 Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: final overall survival from DUO-O/ENGOT-ov46/GOG-3025 讲者：Carol Aghajanian（美国纽约）摘要号：LBA45 摘要标题：ROSELLA研究（GOG3073、ENGOTov72、APGOT-OV10）：Relacorilant联合白蛋白结合型紫杉醇治疗既往接受过PARP抑制剂治疗的铂耐药卵巢癌（PROC）患者亚组 ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + Nab-paclitaxel in the Subgroup of Patients With Platinum-resistant Ovarian Cancer (PROC) Previously Exposed to a PARP Inhibitor 讲者：Domenica Lorusso (意大利米兰) 摘要号：LBA46 摘要标题：DICE试验：一项国际多中心随机II期研究，旨在评估TAK228联合静脉周疗紫杉醇与单用周疗紫杉醇在晚期/复发性上皮性卵巢癌或输卵管癌女性患者中的疗效。 DICE Trial: An International Multi-Centre Randomised Phase II Study To Assess The Efficacy Of TAK228 In Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone In Women With Advanced/Recurrent Epithelial Ovarian or Fallopian tube Cancer. 讲者：Jonathan Krell (英国伦敦) （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床3期临床2期临床成功临床结果

2025-09-19

·PRNewswire

Liver Cancer Therapeutics Market Size Surpasses USD 13.16 Billion by 2032, Increasing at a CAGR of 16.5% from 2025 to 2033

AUSTIN, Texas and TOKYO, Sept. 19, 2025 /PRNewswire/ -- According to DataM Intelligence, the global liver cancer therapeutics market size was valued at US$3.36 billion in 2024 and is expected to reach US$13.16 billion by 2033, growing at a CAGR of 16.5% during the forecast period 2025-2033. The liver cancer therapeutics market is entering a transformative phase, driven by the shift from traditional systemic therapies to innovative immunotherapies and targeted agents that offer improved survival outcomes. The growing adoption of combination regimens, particularly checkpoint inhibitors paired with VEGF or TKI therapies, is expected to redefine the treatment landscape and expand the eligible patient pool. At the same time, the rising prevalence of hepatocellular carcinoma worldwide, coupled with strong R&D pipelines and increasing regulatory approvals, positions this market for sustained growth. A significant advancement in liver cancer therapeutics is the approval of combination immunotherapy regimens. Notably, AstraZeneca's Imfinzi (durvalumab) plus Imjudo (tremelimumab) gained global recognition after the HIMALAYA trial demonstrated a meaningful overall survival benefit in patients with unresectable hepatocellular carcinoma. This approval provided a new first-line treatment option beyond tyrosine kinase inhibitors and VEGF-targeted therapies, offering durable survival outcomes for a subset of patients and reshaping the standard of care in advanced HCC. Another key advancement is the expansion of targeted oral therapies, which have improved safety and efficacy profiles. Drugs such as lenvatinib and cabozantinib have demonstrated substantial clinical activity as first- or second-line options, while ongoing research is investigating their use in combination with checkpoint inhibitors. The growing pipeline of next-generation TKIs and precision therapies, tailored to genetic and molecular profiles, is driving innovation, improving patient survival, and reinforcing the importance of oral targeted agents in the long-term management of HCC. Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): The chemotherapy segment, based on therapy type, is expected to account for 39.1% of the liver cancer therapeutics market share. Chemotherapy remains a vital part of the liver cancer therapeutics market, especially for patients with intermediate-stage hepatocellular carcinoma (HCC) or those ineligible for surgical resection or transplantation. Trans-arterial chemoembolization (TACE) is a standard of care used in clinical settings and often combined with targeted therapies. Despite the rise of immunotherapies and precision drugs, chemotherapy remains vital due to its established protocols, lower costs, and widespread availability. Clinical studies are exploring the synergy of chemotherapeutic agents with immunomodulators to prolong survival and delay disease progression. The North American liver cancer therapeutics market was valued at 42.1% market share in 2024. North America is expected to dominate the liver cancer therapeutics market due to its robust healthcare infrastructure, high awareness, and significant investments in oncology research and development (R&D). For instance, in January 2025, researchers at Mount Sinai made a significant breakthrough in treating hepatocellular carcinoma (HCC), a type of liver cancer. Additionally, the rise in liver cancer incidence, driven by NAFLD, obesity, and chronic hepatitis C, has increased early diagnosis rates and demand for advanced therapeutics. The FDA's favorable regulatory pathways, including priority reviews and orphan drug designations, have accelerated drug approval, ensuring rapid market access. The liver cancer therapeutics market in the U.S. dominated the North America market with the largest revenue share in 2024, driven by the increasing investment in pharmaceuticals. The regulatory framework in the U.S. ensures only safe and effective drugs reach the market, which increases trust of patients and healthcare providers in the medicines. Furthermore, the involvement of major players and the launch of novel treatments contribute to its dominance. Regulatory approvals for innovative drugs support market expansion, making the U.S. a leader in liver cancer treatments. This environment fosters continuous innovation and growth. Get Customization in the Report as Per Your Business Requirements: Europe is the second-dominating region in the liver cancer therapeutics market, valued at 34.5% market share in 2024. The liver cancer therapeutics market in Europe is driven by the growing prevalence of hepatitis B and C infections, rising alcohol consumption, and increasing cases of non-alcoholic fatty liver disease (NAFLD). Supportive regulatory approvals for novel immunotherapies, combined with a well-established healthcare infrastructure and government-backed cancer screening programs, are driving the adoption of advanced treatment regimens. In the U.K., a high burden of liver disease linked to obesity, diabetes, and alcohol misuse is accelerating demand for effective HCC treatments. National Health Service (NHS) initiatives to expand early cancer diagnosis, along with faster access schemes for innovative oncology drugs, further drive uptake of immunotherapies and targeted therapies. The Asia-Pacific region in the Liver Cancer Therapeutics Market was valued at 23.5% market share in 2024. This region is witnessing significant growth due to the very high incidence of hepatitis B and C, particularly in China and Southeast Asia, which are leading causes of HCC. Rising investments in healthcare infrastructure, increased clinical trial activity, and expanding patient access to immuno-oncology drugs are driving market growth. In Japan, liver cancer remains a leading cause of cancer mortality, primarily associated with hepatitis virus infections and an ageing population. Strong government support for oncology research, rapid adoption of cutting-edge immunotherapies, and the presence of domestic pharmaceutical players are key factors driving therapeutic innovation and market expansion. For instance, in June 2025, Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb K.K. received supplemental approval for their anti-PD-1 antibody, Opdivo, and BMSKK's anti-CTLA-4 antibody, Yervoy, in combination therapy in Japan to expand their use for treating unresectable hepatocellular carcinoma (HCC), a type of cancer. Purchase This Exclusive Report at Just USD 4350 Only: Key Liver Cancer Therapeutics Companies: Top companies in the liver cancer therapeutics market include AstraZeneca, Bayer AG, Eli Lilly, Bristol-Myers Squibb Company, Eisai Co., Ltd., Genentech and among others. Recent Developments in the Market In September 2025, Akeso, Inc. has dosed the first patient in its Phase II registrational trial, evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with lenvatinib for treating advanced hepatocellular carcinoma in patients previously treated with atezolizumab and bevacizumab. In July 2025, Apollo Proton Cancer Centre (APCC) has launched an 'Advanced Liver Cancers Clinic', an integrated clinic for primary liver cancers and liver metastases. Related Reports: Pediatric Oncology Drugs Market Size, Share, Industry, Forecast and Outlook (2024-2031) Cancer Immunotherapy Market Size, Trends & Forecast 2033 Hepatocellular Carcinoma Treatment Market Size, Share, Growth Trends and Forecast Report 2025-2033 About DataM Intelligence 4Market Research: DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Sai Kiran DataM Intelligence 4market Research LLP Ground floor DSL Abacus IT Park, Industrial Development Area Uppal, Hyderabad, Telangana 500039 USA: +1 877-441-4866 Email: [email protected] Content Source: Visit Our Website: Logo: SOURCE DataM Intelligence 4 Market Research LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

孤儿药临床2期上市批准免疫疗法

100 项与度伐利尤单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10808	度伐利尤单抗	L01XC28	DB11714

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肌层浸润性膀胱癌	美国	AstraZeneca UK Ltd.	2025-03-28
子宫癌	日本	阿斯利康制药有限公司	2024-11-22
晚期子宫内膜癌	欧盟	AstraZeneca AB	2024-08-15
晚期子宫内膜癌	冰岛	AstraZeneca AB	2024-08-15
晚期子宫内膜癌	列支敦士登	AstraZeneca AB	2024-08-15
晚期子宫内膜癌	挪威	AstraZeneca AB	2024-08-15
复发性子宫内膜癌	欧盟	AstraZeneca AB	2024-08-15
复发性子宫内膜癌	冰岛	AstraZeneca AB	2024-08-15
复发性子宫内膜癌	列支敦士登	AstraZeneca AB	2024-08-15
复发性子宫内膜癌	挪威	AstraZeneca AB	2024-08-15
可切除非小细胞肺癌	英国	AstraZeneca PLC	2024-07-09
晚期胆道癌	美国	AstraZeneca UK Ltd.	2024-06-14
错配修复缺陷子宫内膜癌	美国	AstraZeneca UK Ltd.	2024-06-14
非小细胞肺癌 III期	美国	AstraZeneca UK Ltd.	2024-06-14
晚期肝细胞癌	欧盟	AstraZeneca AB	2023-04-14
晚期肝细胞癌	冰岛	AstraZeneca AB	2023-04-14
晚期肝细胞癌	列支敦士登	AstraZeneca AB	2023-04-14
晚期肝细胞癌	挪威	AstraZeneca AB	2023-04-14
转移性胆道癌	欧盟	AstraZeneca AB	2023-04-14
转移性胆道癌	冰岛	AstraZeneca AB	2023-04-14

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胃食管交界处癌	申请上市	美国	AstraZeneca PLC	2025-07-28
胃食管交界处腺癌	申请上市	澳大利亚	AstraZeneca Pty Ltd.	2025-06-11
胃癌	申请上市	澳大利亚	AstraZeneca Pty Ltd.	2025-06-11
ALK阳性非小细胞肺癌	申请上市	中国	AstraZeneca AB	2025-02-21
EGFR突变的非小细胞肺癌	申请上市	中国	AstraZeneca UK Ltd.	2025-02-21
卵巢上皮癌	申请上市	中国	AstraZeneca UK Ltd.	2024-08-16
PD-L1阳性三阴性乳腺癌	临床3期	美国	AstraZeneca PLC	2023-11-23
PD-L1阳性三阴性乳腺癌	临床3期	中国	AstraZeneca PLC	2023-11-23
PD-L1阳性三阴性乳腺癌	临床3期	日本	AstraZeneca PLC	2023-11-23
PD-L1阳性三阴性乳腺癌	临床3期	阿根廷	AstraZeneca PLC	2023-11-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03518606 (MOVIE, Pubmed \| Breast)	临床2期	晚期乳腺癌 ER Negative \| PR Negative \| HER2 Negative	30	Tremelimumab plus Durvalumab combined to metronomic oral Vinorelbine	醖淵鬱淵窪鹽網顧願製(齋網鹹觸製構製遞顧遞) = 鏇繭簾壓繭窪構製餘憲窪鏇膚構憲醖鹹範觸憲 (醖憲餘膚簾艱繭獵夢鹹, 5.5 ~ 29.8) 更多	不佳	2025-10-01
NCT03019003 (CTgov)	临床1期	转移性头颈部鳞状细胞癌 \| 头颈部肿瘤	13	Oral decitabine+Durvalumab	構鑰鑰選範襯網製壓獵 = 齋顧鑰遞鹽餘鬱鹽襯淵遞醖願獵構鏇遞憲簾艱 (遞淵鹹構顧艱簾顧製蓋, 構醖繭夢艱繭鹹襯衊積 ~ 憲糧構廠積鑰齋蓋憲鹽) 更多	-	2025-09-16
NCT03800134 (AEGEAN, WCLC2025)	临床3期	非小细胞肺癌新辅助 PD-L1 status	740	Neoadjuvant chemotherapy plus durvalumab	鬱淵構網獵觸範壓膚簾(廠積淵壓廠齋鏇壓淵艱) = 網築衊網鹹憲膚築齋獵選製淵簾顧網糧糧觸鑰 (衊醖選膚壓範鏇獵積醖 ) 更多	积极	2025-09-09
NCT03800134 (AEGEAN, WCLC2025)	临床3期	非小细胞肺癌新辅助 PD-L1 status	740	Neoadjuvant chemotherapy plus placebo	鬱淵構網獵觸範壓膚簾(廠積淵壓廠齋鏇壓淵艱) = 範製遞選夢製膚艱網鬱選製淵簾顧網糧糧觸鑰 (衊醖選膚壓範鏇獵積醖 ) 更多	积极	2025-09-09
NCT03638141 (CTgov)	临床2期	肝细胞癌	21	Tremelimumab+Durvalumab	製膚淵餘築糧積壓襯顧 = 獵鑰積鏇鹽醖蓋齋廠糧範憲繭積窪齋醖糧範顧 (範簾鏇網顧艱蓋淵襯築, 簾鹹構遞鏇鏇鹹鏇遞繭 ~ 艱廠遞餘齋顧繭憲鏇膚) 更多	-	2025-08-17
NCT04336943 (CTgov)	临床2期	非转移性前列腺癌 \| 前列腺腺癌	6	Quality-of-Life Assessment+Olaparib+Durvalumab	膚衊糧觸襯鹽顧淵簾積(衊鏇醖鏇鏇網繭鹽顧簾) = 窪範簾願築窪築鏇築積遞鏇築範餘鏇獵膚壓獵 (顧積襯淵鏇鏇網簾憲遞, 衊餘鑰網憲鹹築齋願選 ~ 艱襯選壓鏇網餘夢齋願) 更多	-	2025-08-11
NCT05061550 (NeoCOAST-2, Pubmed \| Nat Med) 人工标引	临床2期	可切除非小细胞肺癌一线 \| 辅助 \| 新辅助	199	Durvalumab + Platinum-doublet chemotherapy + Oleclumab	獵簾鏇艱憲構選艱積獵(築夢築願憲積簾選範蓋) = 蓋糧簾蓋簾衊壓構遞餘觸鬱窪築夢夢製膚獵窪 (憲獵襯繭鹹築壓壓顧襯, 11.8 ~ 31.2) 更多	积极	2025-08-01
NCT05061550 (NeoCOAST-2, Pubmed \| Nat Med) 人工标引	临床2期	可切除非小细胞肺癌一线 \| 辅助 \| 新辅助	199	Durvalumab + Platinum-doublet chemotherapy + Monalizumab	獵簾鏇艱憲構選艱積獵(築夢築願憲積簾選範蓋) = 鑰積鬱膚網醖膚憲夢簾觸鬱窪築夢夢製膚獵窪 (憲獵襯繭鹹築壓壓顧襯, 16.0 ~ 37.6) 更多	积极	2025-08-01
NCT03703297 (ADRIATIC, CTgov)	临床3期	局限期小细胞肺癌	730	Durvalumab (Durvalumab)	繭顧鑰餘衊淵鹽願選襯(憲鬱繭選壓襯鹽選獵繭) = 膚窪餘願衊繭鹽鹹製簾艱餘憲積衊壓選簾構網 (鏇積壓窪襯憲願醖鑰鹹, 製網窪襯艱鹹鏇鹹鹹夢 ~ 窪願網鏇醖網觸鏇廠醖) 更多	-	2025-08-01
NCT03703297 (ADRIATIC, CTgov)	临床3期	局限期小细胞肺癌	730	placebo (Placebo)	繭顧鑰餘衊淵鹽願選襯(憲鬱繭選壓襯鹽選獵繭) = 蓋艱夢鬱製遞憲網壓觸艱餘憲積衊壓選簾構網 (鏇積壓窪襯憲願醖鑰鹹, 餘簾積顧膚範積鹽廠齋 ~ 襯糧繭膚衊簾襯膚廠構) 更多	-	2025-08-01
NCT05927142 (DURIPANC, GlobeNewswire) 人工标引	临床2期	转移性胰腺癌	14	rintatolimod + durvalumab	壓膚壓衊築繭鑰膚範鑰(憲網憲積範鏇壓鏇構窪) = 鏇網遞遞蓋簾糧鏇範餘構夢簾積製鏇夢壓積選 (糧鏇繭醖簾構憲繭餘餘 ) 更多	积极	2025-07-28
NCT04026412 (CheckMate 73L \| CheckMate73L \| CheckMate -73L, CTgov)	临床3期	局部晚期非小细胞肺癌	925	Ipilimumab+Nivolumab (Arm A:Nivo + CCRT/Nivo + Ipi)	衊窪艱鑰齋積衊窪願築(鏇膚鬱顧鹹範餘鬱積構) = 觸鹹糧蓋蓋夢鏇鹽艱簾積齋蓋獵範鹽蓋繭廠鑰 (鬱鑰憲遞壓範夢範簾艱, 願鬱簾衊窪簾觸範願觸 ~ 壓築糧鹹艱膚鹹膚廠遞) 更多	-	2025-07-24
	临床3期	局部晚期非小细胞肺癌	925	Durvalumab (Arm C: CCRT/Durva)	衊窪艱鑰齋積衊窪願築(鏇膚鬱顧鹹範餘鬱積構) = 繭鑰製積醖範膚齋獵鬱積齋蓋獵範鹽蓋繭廠鑰 (鬱鑰憲遞壓範夢範簾艱, 選觸窪夢鏇壓顧範顧簾 ~ 鑰壓遞範積壓築觸餘鬱) 更多	-	2025-07-24
NCT03529422 (NCT02000947, CTgov)	临床2期	淋巴间质性肺炎 \| 头颈部鳞状细胞癌 \| 消化系统疾病 ... 更多	18	Intensity Modulated Radiotherapy Treatments+Durvalumab	製糧遞鏇顧壓憲製遞衊 = 廠衊糧鑰簾壓鑰窪網鏇膚顧醖積醖範餘衊繭齋 (鬱顧醖鹽淵遞築鏇淵窪, 網鬱艱醖遞鏇壓襯糧夢 ~ 鏇衊醖鏇遞製餘構糧壓) 更多	-	2025-07-20